Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 66

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 66
---
 incentive program, which is guided by specified annual corporate and individual goals and contributions, to emphasize pay-for-performanceand to reward our NEOs for our performance during the preceding year. The target pay opportunity of the annual cash incentive for the chief executive officer is determined by our board of directors, based upon the recommendation of our compensation & people committee, and the amount of the target pay opportunity of the annual cash incentive for all other NEOs is determined by our compensation & people committee with input from our chief executive officer. In making such determinations and recommendations, the compensation & people committee examined the totality of anticipated and unanticipated achievements by us and each NEO in the preceding year, including our performance against specific research, clinical, regulatory, operational and financial company goals. In recent years, these annual company goals have primarily focused on the advancement of our most advanced programs. Our compensation & people committee determined to formally cap annual performance-based cash incentive program funding in any given year at 150% of the target payout level. Under our annual performance-based cash incentive program, individual cash incentive awards are determined by first establishing a cash incentive pool, which is adjusted based upon recommendations by our compensation & people committee and upon approval by our board of directors based on the company’s performance as measured against the company’s predetermined annual goals and then allocated among all eligible program participants. Below is the list of the company’s 2024 goals and relative weighting assigned to each goal, as considered by our compensation & people committee and board of directors in their respective assessment of company performance in 2024.

| 1) | Set foundation for future of hemolytic anemia franchise through launch readiness and global planning: relative weighting 35% |

| • |     | Achieve target revenue for PYRUKYND® in adult PK deficiency by the end of the fourth quarter; |

48

| • |     | Ensure launch readiness based on defined metrics by the end of the fourth quarter; and |

| • |     | Ensure ex-U.S. partner(s) and operational engagement plans are secured for prioritized regions by the end of the fourth quarter. |

| 2) | Advance PYRUKYND®, including progressing pivotal programs in thalassemia and SCD: relative weighting 35% |

| • |     | File a supplemental New Drug Application in the United States for thalassemia by the end of the fourth quarter; and |

| • |     | Achieve last-patient-in for the phase 3 portion of our RISE UP